Pharmaceutical

J&J touts success of nipocalimab in two rare disease trials

J&J’s nipocalimab met primary endpoints in Phase III and II trials for myasthenia gravis and Sjogren’s disease, respectively.

Feb 6, 2024 - 18:00
J&J touts success of nipocalimab in two rare disease trials
J&J’s nipocalimab met primary endpoints in Phase III and II trials for myasthenia gravis and Sjogren’s disease, respectively.
Read the original article

Tags:

Previous Article

China NMPA grants IND clearance for Fermion’s TYK2 JH2 inhibitor

Next Article

Health Canada approves Chiesi’s MYALEPTA for lipodystrophy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront

AbbVie licenses OSE’s chronic inflammation therapy for ...

Feb 28, 2024

Manufacturing inspections down in China amid arrest fears and no access

Manufacturing inspections down in China amid arrest fea...

Jun 2, 2024

STAT+: European regulators tout their accomplishments against pharma’s anticompetitive practices

STAT+: European regulators tout their accomplishments a...

Jan 30, 2024